Peptonic Medical signs agreement for distribution of self-test for bacterial vaginosis with exclusivity in Sweden, Norway and Denmark
Stockholm , 1[st] December 2020 - Peptonic Medical AB (publ) ('Peptonic' or 'the company') announces today that they have signed an agreement with Common Sense, Ltd. (Common Sense) on the distribution of a self-diagnostic test for bacterial vaginosis. The distribution rights apply to 28 countries, of which exclusive rights apply to Sweden, Norway and Denmark. Among the non-exclusive countries are e.g. England, Germany, France, Spain, Italy and Australia. Peptonic will launch the self-test under the VagiVital® brand.The self-tests have been developed by Common Sense and are sold today in